Search clinical trials for: AZD0424
Total 162 results
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease | Lung DiseaseBulgaria, Slovakia
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease | Lung DiseaseGermany
-
AstraZenecaCompletedHealthy VolunteersUnited States
-
AstraZenecaCompletedHealthy Volunteer | Coronavirus Disease 2019 (COVID-19)China
-
AstraZenecaRecruitingB-cell Acute Lymphoblastic Leukemia (B-ALL)Spain, Canada, United Kingdom, Italy, Germany, Australia, United States, Taiwan, France, Korea, Republic of, China
-
AstraZenecaParexelWithdrawn
-
AstraZenecaCompleted
-
Peking UniversityAstraZenecaRecruiting
-
AstraZenecaCompleted
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)Completed
-
AstraZenecaNot yet recruitingHepatocellular Carcinoma | Prostate CancerUnited States
-
AstraZenecaParexelRecruitingHeart Failure | Pulmonary Hypertension (World Health Organization Group 2)Netherlands, Spain, Japan, Germany, Austria, Italy, China, Sweden, United Kingdom, United States, Poland, Czechia, Denmark, Canada
-
The Christie NHS Foundation TrustAstraZeneca; University of ManchesterCompleted
-
AstraZenecaCompletedHealthy VolunteersGermany
-
AstraZenecaTerminated
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous CarcinomaUnited States
-
AstraZenecaRecruitingMetastatic Prostate CancerUnited States, Australia
-
AstraZenecaTerminatedLymphoma | Multiple Myeloma | Advanced Solid Tumors | Hematologic MalignanciesUnited States
-
AstraZenecaCompleted
-
Entasis TherapeuticsCompleted
-
AstraZenecaCompletedMelanoma | Malignant MelanomaUnited Kingdom, Netherlands
-
AstraZenecaCompleted
-
AstraZenecaCompletedNon-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,Japan
-
AstraZenecaCompleted
-
AstraZenecaCompletedCoronavirus Disease 2019 (COVID-19)China
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin MelanomaUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedPrimary Peritoneal Carcinoma | Low Grade Ovarian Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Primary Peritoneal Low Grade Serous Adenocarcinoma | Recurrent Borderline Ovarian Surface Epithelial-Stromal TumorUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Diffuse Large Cell LymphomaUnited States
-
Children's Hospital Medical Center, CincinnatiAstraZenecaActive, not recruitingGlioma | Ependymoma | Meningioma | Neurofibromatosis 2 | Vestibular SchwannomaUnited States
-
AstraZenecaCompletedHeart FailureUnited States
-
AstraZenecaCompleted
-
Cancer Research UKTerminatedAdvanced Solid TumoursUnited Kingdom
-
AstraZenecaMerck Sharp & Dohme LLCActive, not recruitingNeurofibromatosis 1 | Plexiform Neurofibroma (PN)United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
-
AstraZenecaActive, not recruitingCancer | TumorUnited States, Netherlands, United Kingdom
-
AstraZenecaCompleted
-
AstraZenecaTerminatedPlaque Psoriasis VulgarisDenmark
-
National Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
Merck Sharp & Dohme LLCAstraZenecaCompletedLocally Advanced or Metastatic Solid Tumors
-
AstraZenecaCompletedHealthy Volunteers Pharmacokinetic StudyUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Neurofibromatosis Type 1 | Refractory Neurofibromatosis Type 1United States
-
National Cancer Institute (NCI)WithdrawnNeoplasms, Nerve Tissue | Peripheral Nervous System Diseases | Heredodegenerative Disorders, Nervous System | Neurofibromatosis 1
-
National Cancer Institute (NCI)Active, not recruitingNeurofibromatosis 1 | Neurofibroma, Plexiform | Neurofibromatosis Type 1 | NF1United States
-
AstraZenecaCompletedBioavailability and AUCUnited Kingdom
-
AstraZenecaCompletedNerve PainSweden, Bulgaria, France, Russian Federation, United Kingdom, Poland, Denmark
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)CompletedNeurofibromatosis Type 1 | Cutaneous Neurofibroma | Optic Nerve GliomaUnited States